Changes in Alzheimer's disease blood biomarkers in patients undergoing lecanemab therapy
Preliminarily analysis revealed that GFAP, p-tau217, and Aβ42/40 had the most frequent post-lecanemab biomarker decreases. Additional sample collection is ongoing to assess the association of AD BBM changes with Amyloid PET over time.
Authors
- Susan Ashrafzadeh‐Kian (ORCID: https://orcid.org/0000-0003-2991-129X)
- Alicia Algeciras‐Schimnich (ORCID: https://orcid.org/0000-0002-4455-6217)
- Joshua A. Bornhorst (ORCID: https://orcid.org/0009-0003-9297-3271)
- Daniel J. Figdore (ORCID: https://orcid.org/0000-0002-4776-3203)
- Jonathan Graff Radford
- Ronald Petersen
- Vijay K. Ramanan
Institutions
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099404
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00